SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells

References

• Lemjabbar-Alaoui H, Hassan OU, Yang YW, et al. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015;1856:189–210.
   PubMed Web of Science ®Google Scholar
• Xu J, Yang H, Jin B, et al. EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. Sci Rep. 2016;6:36371.
   PubMed Web of Science ®Google Scholar
• Jiang AG, Lu HY. k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis. Contemp Oncol (Pozn). 2016;20:124–129.
   PubMed Web of Science ®Google Scholar
• Westcott PM, Halliwill KD, To MD, et al. The mutational landscapes of genetic and chemical models of KRAS-driven lung cancer. Nature. 2015;517:489–492.
   PubMed Web of Science ®Google Scholar
• Kim WY, Prudkin L, Feng L, et al. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012;118:3993–4003.
   PubMed Web of Science ®Google Scholar
• Mainardi S, Mulero-Sanchez A, Prahallad A, et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med. 2018;24:961–967.
   PubMed Web of Science ®Google Scholar
• Grossmann KS, Rosario M, Birchmeier C, et al. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res. 2010;106:53–89.
   PubMed Web of Science ®Google Scholar
• Zheng L, Guo Q, Xiang C, et al. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells. J Hematol Oncol. 2019;12:23.
   PubMed Web of Science ®Google Scholar
• Kubara K, Yamazaki K, Ishihara Y, et al. Status of KRAS in iPSCs impacts upon self-renewal and differentiation propensity. Stem Cell Rep. 2018;11:380–394.
   PubMed Web of Science ®Google Scholar
• Khosravi N, Caetano MS, Cumpian AM, et al. IL22 promotes KRAS-mutant lung cancer by induction of a protumor immune response and protection of stemness properties. Cancer Immunol Res. 2018;6:788–797.
   PubMed Web of Science ®Google Scholar
• Ghazvini M, Sonneveld P, Kremer A, et al. Cancer stemness in Apc- vs. Apc/KRAS-driven intestinal tumorigenesis. PloS One. 2013;8:e73872.
   PubMed Web of Science ®Google Scholar
• Xiao P, Guo Y, Zhang H, et al. Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment. Oncogene. 2018;37:5088–5100.
   PubMed Web of Science ®Google Scholar
• Zhao H, Martin E, Matalkah F, et al. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene. 2019;38:2275–2290.
   PubMed Web of Science ®Google Scholar
• Cai Z, Hao XY, Liu FX. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression. Arch Oral Biol. 2018;89:20–25.
   PubMed Web of Science ®Google Scholar
• Yang CY, Chang PW, Hsu WH, et al. Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration. Oncogene. 2019;38:4075–4094.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang J, Qi T, et al. SHP2 protects endothelial cell barrier through suppressing VE-cadherin internalization regulated by MET-ARF1. FASEB J. 2019;33:1124–1137.
   PubMed Web of Science ®Google Scholar
• Zheng L, Xiang C, Li X, et al. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol Oncol. 2018;11:72
   PubMed Web of Science ®Google Scholar
• Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24:512–517.
   PubMed Web of Science ®Google Scholar
• Fedele C, Ran H, Diskin B, et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 2018;8:1237–1249.
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Adamopoulos C, Karoulia Z, et al. SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors. Cell Rep. 2019;26:65–78 e65.
   PubMed Web of Science ®Google Scholar
• Choi E, Kikuchi S, Gao H, et al. Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. Nat Commun. 2019;10:1473
   PubMed Web of Science ®Google Scholar
• Lu H, Liu C, Velazquez R, et al. SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors. Mol Cancer Ther. 2019;18:1323.
   PubMed Web of Science ®Google Scholar
• Ryu HH, Kim T, Kim JW, et al. Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory. Sci Signal. 2019;12: pii: eaau5755.
   PubMed Web of Science ®Google Scholar